CEL SCI CORP (CVM)

5.26 0 (0%)

As of 2025-12-31 16:33:51 EST

Cel-Sci Corporation (NYSE American: CVM), is a biotechnology company that tests drugs for the treatment of cancer, autoimmune and infectious diseases through the research and development of immunotherapy products.

Traded asNYSE: CVM
ISINUS1508377066
CIK0000725363
LEI549300FIWOFSETIVMI17
EIN840916344
Sector—
IndustryBiological Products, (No Diagnostic Substances)
CEO—
Employees—
Fiscal Year End0930
Address8229 BOONE BLVD ., VIENNA, VA, 22182
Phone7035069460
Websitehttps://cel-sci.com/
Stock Quotes
trading_symbolregistrant_nametimepricechangepercentage_change
CVMCEL SCI CORP2025-12-31 16:33:515.2600
This is a preview of the latest data. Subscribe to access the full data.
Company Information
trading_symbolcentral_index_keyregistrant_nameisin_numberlei_numberein_numberexchangesic_codesic_descriptionfiscal_year_endstate_of_incorporationaddress_streetaddress_cityaddress_stateaddress_zip_codeaddress_countryaddress_country_codephone_numbermailing_addressbusiness_addressformer_nameindustryfounding_datechief_executive_officernumber_of_employeeswebsitemarket_capshares_issuedshares_outstandingdescriptionupdate_time
CVM0000725363CEL SCI CORPUS1508377066549300FIWOFSETIVMI17840916344NYSE2836Biological Products, (No Diagnostic Substances)0930CO8229 BOONE BLVD .VIENNAVA22182UNITED STATESUS70350694608229 BOONE BLVD., VIENNA, VA, 221828229 BOONE BLVD ., VIENNA, VA, 22182——1983——https://cel-sci.com/100,002,1895,321,3416,882,156Cel-Sci Corporation (NYSE American: CVM), is a biotechnology company that tests drugs for the treatment of cancer, autoimmune and infectious diseases through the research and development of immunotherapy products.2025-12-25 21:44:47
This is a preview of the latest data. Subscribe to access the full data.
CVM Stock Price (End-of-Day)
This is a preview of the latest data. Subscribe to access the full data.
CVM Stock Price (1-Minute)
This is a preview of the latest data. Subscribe to access the full data.
Market Cap
Fiscal YearMarket CapChange In Market CapPercentage Change In Market CapShares OutstandingChange In Shares OutstandingPercentage Change In Shares Outstanding
2024100,002,1892,362,8942.4274,107,04124,126,23748.271
202397,639,295-65,929,498-40.306949,980,8046,300,94114.4253
2022163,568,793-431,969,114-72.534343,679,863435,3651.0068
This is a preview of the latest data. Subscribe to access the full data.
Executive Compensation
Executive NameExecutive PositionFiscal YearSalaryBonusStock AwardsIncentive Plan CompensationOther CompensationTotal Compensation
Eyal TalorChief Scientific Officer2024349,61209,600—6,031613,023
John CiprianoSenior Vice President2024249,56200—31249,593
Geert R. KerstenChief Executive And Financial Officer, Treasurer2024644,091020,475—65,6311,070,554
Patricia B. PrichepSecretary, Senior Vice President2024289,194017,160—9,031542,744
Daniel Zimmerman, Ph.D.Senior Vice President202345,54600—53146,077
This is a preview of the latest data. Subscribe to access the full data.
Employee Count
Fiscal YearEmployee Count
201144
This is a preview of the latest data. Subscribe to access the full data.
Income Statements
Fiscal Year202520242023
Revenue———
Cost Of Revenue———
Gross Profit———
Research And Development Expenses15,886,97718,161,45122,471,496
General And Administrative Expenses8,922,7598,191,0239,004,578
Operating Expenses24,809,73626,352,47431,476,074
Operating Income-24,809,736-26,352,474-31,476,074
Net Income-25,411,055-27,579,921-32,194,303
Earnings Per Share Basic——-0.73
Earnings Per Share Diluted-6.27-0.51—
Weighted Average Shares Outstanding Basic——44,479,865
Weighted Average Shares Outstanding Diluted4,055,73854,044,989—
This is a preview of the latest data. Subscribe to access the full data.
Balance Sheet Statements
Fiscal Year202520242023
Cash And Cash Equivalents10,953,4604,738,1734,145,735
Marketable Securities Current———
Accounts Receivable———
Inventories—1,019,9082,248,072
Non Trade Receivables———
Other Assets Current332,301294,097520,368
Total Assets Current11,596,1286,055,6786,918,420
Marketable Securities Non Current———
Property Plant And Equipment6,079,2958,129,75310,188,126
Other Assets Non Current———
Total Assets Non Current16,559,62020,936,08823,609,830
Total Assets28,155,74826,991,76630,528,250
Accounts Payable1,061,3511,448,4672,009,786
Deferred Revenue———
Short Term Debt2,274,000——
Other Liabilities Current711,820566,0421,049,581
Total Liabilities Current5,130,5464,615,7795,585,846
Long Term Debt5,684,000—9,949,000
Other Liabilities Non Current125,000125,000125,000
Total Liabilities Non Current7,068,1179,508,90411,727,514
Total Liabilities12,198,66314,124,68317,313,360
Common Stock80,157637,870474,223
Retained Earnings-539,422,916-514,011,861-487,091,396
Accumulated Other Comprehensive Income———
Total Shareholders Equity15,957,08512,867,08313,214,890
This is a preview of the latest data. Subscribe to access the full data.
Cash Flow Statements
Fiscal Year202520242023
Depreciation And Amortization3,885,1533,969,1833,958,334
Share Based Compensation Expense1,910,9974,270,1806,286,231
Other Non Cash Income Expense———
Change In Accounts Receivable———
Change In Inventories-973,665172,608-156,727
Change In Non Trade Receivables———
Change In Other Assets———
Change In Accounts Payable-442,710-460,576257,845
Change In Other Liabilities120,728-458,489207,089
Cash From Operating Activities-17,119,737-18,811,206-22,848,561
Purchases Of Marketable Securities———
Sales Of Marketable Securities———
Acquisition Of Property Plant And Equipment38,10994,875361,892
Acquisition Of Business———
Other Investing Activities———
Cash From Investing Activities-38,109-108,086-372,262
Tax Withholding For Share Based Compensation———
Payments Of Dividends———
Issuance Of Common Stock28,291,10023,575,000—
Repurchase Of Common Stock———
Issuance Of Long Term Debt———
Repayment Of Long Term Debt———
Other Financing Activities—80,620—
Cash From Financing Activities23,373,13319,511,7304,694,420
Change In Cash6,215,287592,438-18,526,403
Cash At End Of Period10,953,4604,738,1734,145,735
Income Taxes Paid———
Interest Paid768,466923,8071,062,564
This is a preview of the latest data. Subscribe to access the full data.
Key Metrics
Fiscal Year202520242023
Earnings Per Share——-0.73
Price To Earnings Ratio——-51.3751
Earnings Growth Rate——-16.092
Price Earnings To Growth Ratio——3.1926
Book Value Per Share——0.2971
Price To Book Ratio——126.2337
Ebitda-20,876,902-22,865,065-27,560,553
Enterprise Value——1,673,967,225.987
Dividend Yield———
Dividend Payout Ratio———
Debt To Equity Ratio0.4987—0.7529
Capital Expenditures1,834,6951,910,8102,257,431
Free Cash Flow-18,954,432-20,722,016-25,105,992
Return On Equity-1.5925-2.1434-2.4362
One Year Beta0.5071.5741.0871
Three Year Beta0.91171.41941.0251
Five Year Beta0.95290.88140.9357
This is a preview of the latest data. Subscribe to access the full data.
Insider Transactions
Insider NameRelationship To IssuerTransaction DateAmount Of SecuritiesAcquired Or DisposedSecurities Owned Following Transaction
KERSTEN GEERT RDirector, Chief Executive Officer2025-12-048,389A81,794
KERSTEN GEERT RDirector, Chief Executive Officer2025-09-30570A73,405
PRICHEP PATRICIA BChief Financial Officer2025-09-30466A11,213
TALOR EYALChief Scientific Officer2025-09-30260A5,808
KERSTEN GEERT RDirector, Chief Executive Officer2025-07-2825,000A175,157
This is a preview of the latest data. Subscribe to access the full data.
Institutional Holdings
Investor NamePeriod Of ReportMarket ValueAmount Of SecuritiesPrice Per Security
Allworth Financial LP2025-09-303749.25
JPMORGAN CHASE & CO2025-09-306479.1429
Advisory Services Network, LLC2025-09-308399.2222
NewEdge Advisors, LLC2025-09-30239269.1923
NORTHERN TRUST CORP2025-09-30130,68614,2059.2
This is a preview of the latest data. Subscribe to access the full data.
Mutual Fund Holdings
Registrant NamePeriod Of ReportFund NameFund SymbolAmount Of UnitsValue In UsdPercentage Value Compared To Assets
VANGUARD INDEX FUNDS2025-09-30Institutional Select SharesVSEMX95,308876,833.60.001
VANGUARD INDEX FUNDS2025-09-30Institutional Plus SharesVEMPX95,308876,833.60.001
VANGUARD INDEX FUNDS2025-09-30ETF SharesVXF95,308876,833.60.001
VANGUARD INDEX FUNDS2025-09-30Institutional SharesVIEIX95,308876,833.60.001
VANGUARD INDEX FUNDS2025-09-30Admiral SharesVEXAX95,308876,833.60.001
This is a preview of the latest data. Subscribe to access the full data.